延续昨日强势,MIRXES-B(2629.HK)今日盘中再度飙升,一度涨超35%,报75港元,股价再创上市新高,市值突破200亿港元。
Mirxes是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司,致力于使疾病筛查诊断解决方案在亚洲关键市场触手可及。
恒生指数公司此前公告,Mirxes(觅瑞)获纳入恒生综合指数,相关变动已于9月8日起生效,该公司也已正式成为港股通标的。该股自5月23日上市至今,不到4个月时间,股价(较IPO价格23.3港元)已累涨220%。

延续昨日强势,MIRXES-B(2629.HK)今日盘中再度飙升,一度涨超35%,报75港元,股价再创上市新高,市值突破200亿港元。
Mirxes是一家总部位于新加坡的微小核糖核酸(miRNA)技术公司,致力于使疾病筛查诊断解决方案在亚洲关键市场触手可及。
恒生指数公司此前公告,Mirxes(觅瑞)获纳入恒生综合指数,相关变动已于9月8日起生效,该公司也已正式成为港股通标的。该股自5月23日上市至今,不到4个月时间,股价(较IPO价格23.3港元)已累涨220%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.